How big data can help Prostate Cancer Patients
Innovative Medicines Initiative approves € 12 million public-private research project for improved care of prostate cancer patients.
Amsterdam, Netherlands, May 14, 2018: The Innovative Medicines Initiative (IMI) has approved PIONEER, a brand new five-year project, involving 32 partners across 9 countries. PIONEER’s goal is to ensure the optimal care for all European men diagnosed with prostate cancer by unlocking the potential of big data and big data analytics.
On May 14th, the members of the PIONEER consortium (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope) participated in the launch of a new public-private Pan-European prostate cancer research initiative in Amsterdam. ‘PIONEER will harness the power of big data to transform the field of prostate cancer research from the perspective of all relevant stakeholders including clinicians, pharmaceutical companies, payers and most importantly patients’, Prof. James N’Dow, PIONEER Coordinator.
Prostate cancer is the most common cancer diagnosed in men in Europe, representing 1 in 10 of all cancer deaths in men1. Prostate cancer healthcare costs were estimated at €8.43 billion per year in the EU in 2009 and accounted for 7% of all cancer costs in Europe2.
“It is time for research to help future men to give the best diagnosis and treatment so no man should suffer from this silent disease. This programme will assist the awareness of Prostate Cancer in men” Ken Mastris, Prostate Cancer Survivor, ECPC Board member.
At present, there are a number of critical knowledge gaps in relation to the screening, diagnosis and treatment of prostate cancer patients, including:
- lack of standardisation of prostate cancer definitions across all stages of the disease;
- insufficient knowledge of the risk factors for developing prostate cancer;
- insufficient knowledge of patient characteristics, including genetic profiles, for optimal stratification of patients at time of diagnosis;
- lack of meaningful engagement of all key stakeholders, including patients, when defining core disease outcome sets;
- lack of effective implementation of knowledge gained into clinical practice including knowledge informed by real-world data.
This lack of knowledge means that predicting which patients will have the best outcomes with specific treatments is suboptimal, whilst prediction of which patients may be managed safely without treatment remains poor.
PIONEER’s unique approach is to firstly identify critical evidence gaps in prostate cancer care through a detailed prioritisation exercise including all stakeholders: clinicians, patients, researchers, pharmaceutical industry, and payers. PIONEER will then standardise and integrate existing ‘big data’ from quality multidisciplinary data sources into a single innovative data platform, which will leverage two existing data platforms, tranSMART and OHDSI, developed in previous IMI projects. This will result in a unique and comprehensive data set that consists of the most relevant prostate cancer clinical trials and registries, large epidemiological cohorts, electronic health records, and real-world data from different European and non-European patient populations. Based on a unique set of methodologies and advanced analytical methods,
PIONEER will transform the field of prostate cancer care with particular focus on improving prostate cancer-related outcomes, health system efficiency and the quality of health and social care. In addition, PIONEER will provide recommendations for standardised care pathways for clinical centres across Europe.
The use of these data sets during and beyond PIONEER will be Findable, Accessible, Interoperable and Reusable (FAIR) both for human and machine-driven activities. This will increase their interoperability with current and future multifactorial prostate cancer datasets. Lastly, PIONEER will use ‘big data’ to test new prognostic algorithms to provide new hypotheses for future high quality prospective studies, and where appropriate, for implementation into daily clinical practice.
PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492 and is part of the Big Data for Better Outcomes Programme (BD4BO). IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
PIONEER consortium members:
The consortium is being jointly led by Prof. James N’Dow from the European Association of Urology/University of Aberdeen and Dr. Alex Asiimwe from Bayer, and consists of 32 private and public stakeholders in prostate cancer research and clinical care from across 9 countries:
Cancer Intelligence Limited
European Alliance for Personalised Medicine
European Association of Urology
European Cancer Patient Coalition
European Institute for Systems Biology and Medicine
European Organisation for Research and Treatment of Cancer
Erasmus Universitair Medisch Centrum Rotterdam
Imperial College of Science Technology and Medicine
International Consortium for Health Outcomes Measurement
King's College London
Pinsent Masons LLP
Radboud University Medical Center
Swedish Institute for Health Economics
Technische Universität Dresden
The Hyve B.V
The University Court of the University of Aberdeen
University of Tampere
Universita Vita-Salute San Raffaele
Varian Medical Systems
Weizmann Institute of Science
- Ferlay, J., et al., Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 2013. 49(6): p. 1374-403.
- Luengo-Fernandez, R., et al., Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol, 2013. 14(12): p. 1165-74.